Amneal Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Amneal Pharmaceuticals has been growing earnings at an average annual rate of 19.3%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 7.3% per year.
Key information
19.3%
Earnings growth rate
23.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 7.3% |
| Return on equity | -79.5% |
| Net Margin | -3.5% |
| Next Earnings Update | 03 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Amneal Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,394 | -84 | 430 | 164 |
| 30 Sep 23 | 2,386 | 10 | 423 | 160 |
| 30 Jun 23 | 2,312 | -2 | 410 | 169 |
| 31 Mar 23 | 2,272 | -135 | 403 | 182 |
| 31 Dec 22 | 2,212 | -130 | 400 | 196 |
| 30 Sep 22 | 2,139 | -132 | 395 | 206 |
| 30 Jun 22 | 2,122 | -134 | 386 | 204 |
| 31 Mar 22 | 2,098 | 2 | 373 | 206 |
| 31 Dec 21 | 2,094 | 11 | 366 | 202 |
| 30 Sep 21 | 2,067 | 14 | 353 | 203 |
| 30 Jun 21 | 2,058 | 9 | 345 | 199 |
| 31 Mar 21 | 1,987 | -17 | 339 | 192 |
| 31 Dec 20 | 1,993 | 91 | 327 | 180 |
| 30 Sep 20 | 1,880 | 62 | 316 | 175 |
| 30 Jun 20 | 1,739 | -194 | 297 | 168 |
| 31 Mar 20 | 1,679 | -199 | 283 | 171 |
| 31 Dec 19 | 1,626 | -362 | 290 | 188 |
| 30 Sep 19 | 1,727 | -339 | 287 | 197 |
| 30 Jun 19 | 1,825 | -67 | 298 | 202 |
| 31 Mar 19 | 1,834 | -69 | 287 | 204 |
| 31 Dec 18 | 1,663 | -21 | 228 | 194 |
| 30 Sep 18 | 1,459 | 155 | 184 | 180 |
| 30 Jun 18 | 1,237 | 149 | 136 | 179 |
| 31 Mar 18 | 1,083 | 168 | 106 | 176 |
| 31 Dec 17 | 1,034 | 168 | 109 | 171 |
| 30 Sep 17 | 1,039 | 54 | 113 | 171 |
| 31 Dec 16 | 1,018 | 207 | 119 | 179 |
| 31 Dec 15 | 866 | 169 | 110 | 137 |
| 31 Dec 14 | 786 | 177 | 85 | 107 |
Quality Earnings: 2DT is currently unprofitable.
Growing Profit Margin: 2DT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2DT is unprofitable, but has reduced losses over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare 2DT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2DT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 2DT has a negative Return on Equity (-79.48%), as it is currently unprofitable.